Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MEDROXYPROGESTERONE ACETATE

All injection strengths: listing conditions apply

Other products in the same Health Canada class (G03A, G03AC) — coverage varies; not interchangeable

  • Drospirenone (Slynd): general benefit
  • Norethindrone (Micronor): general benefit, Not a benefit
  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, Not a benefit
  • Ethinyl estradiol + norethindrone (Brevicon): general benefit

3 more in the class list below

Depo-Provera · DIN 02523493 · 150mg/mL · injection solution-1mL pre-filled syringe

Temporary benefitMarketed · checked 2026-09-19
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Depo-Provera · DIN 02523493 Manufacturer: Pfizer Canada Inc.; listing date 2022-08-31 Health Canada: Marketed since 2022-04-25 · brand DEPO-PROVERA · ATC G03AC06 MEDROXYPROGESTERONE · form Suspension · route Intramuscular · ingredients MEDROXYPROGESTERONE ACETATE 150 MG/ML · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Depo-Provera: Formulary list price $34.7886/unit (unit not stated in source; not the patient's cost)

Ministry pays: $34.7886 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101256 · Verify on the e-Formulary ↗ (DIN 02523493)

Source record
DIN 02523493: Depo-Provera Raw flags: sec3c=Y Item: 683200118; group id 801; item number 1958; lccId None; manufacturer id PFI Source form: Inj Sol-1mL Pref Syr; strength: 150mg/mL Recorded listing: Temporary benefit (shortage substitute) Source prices (unrounded): $34.7886; ministry $34.7886 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523493 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101256
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, ETHINYL ESTRADIOL & NORETHINDRONE, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, LEVONORGESTREL Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL 68:32 Progestogens and Oral Contraceptives

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

NORETHINDRONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 0.35mg · Tab-28 Pk

DESOGESTREL & ETHINYL ESTRADIOL

· 12 products · General benefit · strengths: 0.15mg & 0.03mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tabs-21 Pk, Tabs-28 Pk

DROSPIRENONE & ETHINYL ESTRADIOL

· 9 products · General benefit · strengths: 3.0mg & 0.03mg, 3.0mg & 0.02mg · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & LEVONORGESTREL

· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk

ETHINYL ESTRADIOL & NORETHINDRONE

· 6 products · General benefit · strengths: 0.035mg & 0.5mg, 0.035mg & 1mg, 3 Phase · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & NORETHINDRONE ACETATE

· 4 products · General benefit · strengths: 0.02mg & 1mg, 0.03mg & 1.5mg · Tab-21 Pk, Tab-28 Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

NORGESTIMATE & ETHINYL ESTRADIOL

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg & 0.035mg · Tab-21 Pk

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications AA-MEDROXY (medroxyprogesterone acetate tablets) is indicated for: • Hormonal replacement therapy, to oppose the effects of estrogen on the endometrium and significantly reduce the risk of hyperplasia and carcinoma; • Functional menstrual disorders due to hormonal imbalance in non-pregnant women, in the absence of organic pathology; • Adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial carcinoma; • Adjunctive and/or palliative treatment of hormonally-dependent, recurrent metastatic breast cancer in postmenopausal women. For indications not including breast cancer, AA-MEDROXY should be prescribed only to women with intact uteri. 1.1. Pediatrics Pediatrics (<16 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics Geriatrics (> 65 years of age): see 7 Warnings and precautions, 7.1.4 Geriatrics. https://pdf.hres.ca/dpd_pm/00085517.PDF PM date: 2026-07-24 Source product: AA-MEDROXY; DIN 02244726; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.